Moving Medicine Forward – Details, episodes & analysis

In this special 25th-anniversary episode of "Moving Medicine Forward" - The Podcast, we're excited to welcome Tim Schroeder, Chief Executive Officer of CTI, Lynn Fallon, CTI Board Member and former President, and Kevin Schwarz, Chief Operating Officer of CTI. They share insights into CTI’s founding vision and its evolution over the past quarter-century. Tim and Kevin also discuss how CTI has driven innovation and contributed to the growth of the clinical research industry, highlighting key milestones such as their involvement in over 200 drug approvals. Join us as we celebrate this milestone and explore CTI's journey!  

In this episode of "Moving Medicine Forward" – The Podcast, Dr. Monica Shah, Chief Medical Officer at CTI, discusses her journey into clinical research and her transition into her new role. Dr. Shah shares her immediate priorities and goals as CMO, her leadership style, and her approach to fostering collaboration within CTI. She also expresses her enthusiasm for the upcoming ARM Cell & Gene Meeting on the Mesa, highlighting the key topics and discussions she anticipates. Tune in to gain insights into Dr. Shah’s vision for her role at CTI and learn about her personal interests outside of work. 

0:25 Meet Today’s Guest: Dr. Monica Shah, Chief Medical Officer at CTI. 

0:30 Dr. Shah delves into her background and her journey into the field of clinical research. 

6:50 Dr. Shah outlines her immediate priorities and goals as the new CMO. 

8:05 Dr. Shah’s leadership style and how she plans to foster collaboration at CTI. 

8:55 Dr. Shah shares her excitement about the upcoming ARM Cell & Gene Meeting on the Mesa. 

10:20 Insights into the key topics and discussions Dr. Shah anticipates at the Meeting on the Mesa. 

12:48 Dr. Shah reveals what she’s most excited about in joining the CTI team. 

13:24 Learn about Dr. Shah’s interests and passions outside of her professional life. 

In this episode we delve into the world of regulatory interactions, strategy, & operations with two industry leaders: Dr. Monica Rodriguez, Executive Director of Model-Informed Development, & Christine Norman-Tiner, Executive Director of Global Regulatory & Scientific Affairs. They share their invaluable expertise on: 

• Developing effective regulatory strategies for clinical trials  

• Navigating challenges in global regulatory communications  

• The influence of model-informed development on regulatory practices  

Explore how emerging technologies, patient-centric trials, & real-world evidence are transforming the biotech landscape.

In episode 6 of Moving Medicine Forward, we dive into diversity in clinical research with insights from CTI’s CEO Tim Schroeder and Board Member Dr. Bill Fitzsimmons. Hear about Bill's journey into clinical research, the importance of diversity in clinical trials, and strategies to overcome medical mistrust. We also discuss the latest FDA guidance on diversity* and CTI’s initiatives to foster inclusive practices. 

0:29 - Introduction of guests, Tim Schroeder, CEO of CTI, and Bill Fitzsimmons, CTI Board Member.  

2:20 - Bill shares his journey into clinical research and how he became involved with CTI. 

2:45 - Bill's role and responsibilities as a CTI board member. 

3:36 - Defining diversity in clinical research. 

4:10 - The importance of diversity in clinical trials. 

7:15 - Strategies to encourage participation in clinical trials despite medical mistrust. 

12:54 - Reference to Adam Roth’s episode on vaccine trials during COVID-19: Clinical Research Site Spotlight - Vaccine Trials by Moving Medicine Forward (spotify.com) 

13:00 - Challenges in maintaining diversity within clinical trials. 

14:52 - Impact of regulations and strict requirements for diverse populations on the clinical trial process. 

*15:15 - The FDA guidance on diversity in clinical trials mentioned during the episode has since been published. Please note that the episode was recorded prior to its release. 

19:23 - Essential support needed for clinical trial sites to successfully recruit diverse populations. 

20:57 - Role of CROs in supporting sites to recruit diverse populations. 

23:38 - Improving health and research literacy to enhance participation. 

28:56 - CTI’s initiatives to enhance diversity in clinical research. 

Episode 5 assembles experts in transplantation. Tim Schroeder and Dr. Bill Fitzsimmons join us to discuss how CTI has been a key player in the field of transplantation, current trends, and where the future of transplantation is heading. Dr. Robert Gatson discusses transplantation innovations and his own background in the field. 

Episode 4 assembles various CTI experts to discuss Cell and Gene Therapy. In episode 4, Bret Marshall, joins us to discuss CTI’s involvement in Cardiac Cell and Gene trials, our impact, and goals, as well as the current industry trends and advocacy groups. Jaclyn Guillory discussed the groundbreaking advancements in targeted therapies for KRAS mutations. Later in the episode, Michael Schmidt and Nicole Sparshott joined to discuss cell product chain of custody. Concluding with Joana Lancastre’s discussion on feasibility in cell and gene therapy.  

Today on Moving medicine forward we have a great discussion with Adam Roth, Vice President, Research Site Services at CTI. In this conversation we take a deep dive into how our Clinical Research Center in Cincinnati OH supports clinical research. We focus on the work the site has done on Vaccine trials including how the site supported the Covid-19 Vaccine trials during the pandemic.

On this episode of “Moving Medicine Forward” - The Podcast, we delve into groundbreaking research with Dr. Richard Curry, Medical Director at CTI. Dr. Curry offers an in-depth look at the ongoing Bexion BXQ350 study, shedding light on the significant advancements and the journey of the trials over recent months. This innovative therapy holds promise for revolutionizing cancer treatment, and Dr. Curry's insights provide a glimpse into the future of medical science. 

In the episode's second segment, we're joined by therapeutic leads Chad Jones and Katie Westerkamp, who bring their expertise in hematology and oncology research to the forefront. They discuss the cutting-edge approaches being explored in their fields, emphasizing the importance of innovative therapies in battling cancer. Chad and Katie share their experiences from clinical trials, offering listeners a rare peek into the challenges and triumphs of oncology research. 

Listeners will leave this episode with a deeper understanding of the complexities of cancer research, the importance of ongoing clinical trials, and the collaborative effort required to move medicine forward. This episode not only informs but also inspires, showcasing the tireless work of individuals like Dr. Curry, Chad, and Katie, who are at the forefront of transforming patient care through scientific discovery. 

[1:05] Dive into the origins of the pivotal Bexion BXQ350 study: Discover the compelling history and purpose behind its inception, providing hope and new directions in cancer research. 

[2:25] The pivotal moment neuropathy became a focus: Learn how this challenging condition spurred the initiation of a crucial trial, aiming to bring relief to many. 

[2:56] Explaining neuropathy: An introduction to neuropathy is followed by the announcement of an innovative clinical study aimed at finding effective treatments. 

[4:38] The ongoing search for a cure: A candid discussion on the current state of neuropathy treatment and the relentless pursuit of a cure. 

[5:23] The collaboration that could change the future: Discover how CTI and Bexion joined forces, marking a significant milestone in the journey towards groundbreaking therapies. 

[6:08] From inception to impact: A chronological exploration of the trial's evolution, showcasing the milestones achieved through years of dedicated research. 

[7:28] Breaking new ground with a Phase I trial: An in-depth explanation of the trial's expansion, illustrating the critical steps forward in the fight against cancer. 

[9:04] The expansive network driving the study: An overview of the numerous sites involved in the study, highlighting the collaborative effort across the globe. 

[9:29] A focused approach: Insight into why the trial is uniquely dedicated to cancer patients, underscoring the targeted efforts to combat the disease. 

[14:06] The science behind BXQ350: Delve into the structure and mechanism of the drug, understanding its potential to make a significant impact in cancer treatment. 

[16:18] The critical role of cancer research: Reflect on why pursuing oncology research is not just important but imperative for medical advancement. 

[17:58] Dr. Curry's journey to oncology: Discover the inspiring path Dr. Richard Curry took to become a leading figure in oncology research and his vision for the future.  

 
[20:07] Embarking on a New Perspective: The episode transitions, bringing into focus Chad Jones and Katie Westerkamp, who offer a fresh perspective on the relentless pursuit of breakthroughs in cancer treatment. 

[20:31] Facing the Challenges Head-On: Delve into the unique obstacles encountered in hematology and oncology research.

[21:28] Accelerating Treatment Delivery: Learn how research sites become pivotal in fast-tracking treatments to patients.

[21:59] Integrating Diverse Therapeutic Approaches: Unpack the roles of cell therapy and small molecule research within the trials.

Today for our very first episode We will be talking with Christine Eby director of clinical project management and the Therapeutic lead for Rare Disease here at CTI. She will be sharing her son’s patient Journey as her family navigates his Type 1 diabetes Diagnosis. 

CTI Clinical Trial and Consulting Services presents Moving Medicine Forward, a podcast centered on advancements in healthcare and elevating individual’s stories and expertise. CTI, a global Contract Research organization with associates in 60 countries, has contributed to 10,000+ projects, 200+ drug and device approvals, and 300+ pharmaceutical and emerging biotechnology partners. Our group of innovative thinkers work to change the lives of chronically and critically ill patients.